DDReg pharma

Quailty Driven by Passion

Submit Query

Insights

Home » Insights » Page 2

Importance of Collaboration between Global Regulators

Insights, Regulatory /

Regulatory authorities across the globe play a pivotal role in safeguarding patient safety and ensure regulatory compliance. Each authority functions in its unique way to uphold standards and ultimately ensure the well-being of individuals. In the UK, the MHRA shoulders the vital responsibility of ensuring that medicines, medical devices, blood components for transfusion are safe, of […]

Importance of Collaboration between Global Regulators Read More »

The Advancements of Gene Editing Technology for Safe and Effective Gene Therapy Products

Clinical Regulatory, Insights, Regulatory /

The field of gene therapy has witnessed significant advancements with the development of genome editing technologies. These technologies allow scientists to break, modify, and edit specific genes in a DNA sequence-specific manner, opening up new possibilities for gene therapy. While traditional gene therapy involves the addition of new genes to human cells or tissue, genome

The Advancements of Gene Editing Technology for Safe and Effective Gene Therapy Products Read More »

Navigating Drug Manufacturing Inspections

Insights, Regulatory /

The US FDA conducts drug manufacturing inspections for facilities to ensure they are compliant with the Current Good Manufacturing Practice (cGMP) standards. However, navigating through these inspections requires a clear and comprehensive understanding of several aspects. These include applicable manufacturing standards, site selection model, 483 forms, and how the FDA reviews the inspections and outcomes.

Navigating Drug Manufacturing Inspections Read More »

How does EMA use Artificial Intelligence and Large Language Models in Medicine Regulation?

Insights, Regulatory /

Artificial Intelligence in Medicine Regulation– a perspective by Emer Cooke, Executive Director of the European Medicines Agency. Introduction Artificial Intelligence (AI) is revolutionizing the regulation of medicines by offering innovative solutions to enhance drug safety, efficacy, and overall patient well-being. With its ability to process vast amounts of data, identify patterns, and predict potential risks,

How does EMA use Artificial Intelligence and Large Language Models in Medicine Regulation? Read More »

Post-market safety data for underrepresented populations in clinical trials

Blogs, Pharmacovigilance /

Introduction Regulatory agencies require sponsors to collect and provide data on the safety and efficacy of drugs that they have obtained from clinical trials. In addition to age, gender, and racial subgroups, these trials should also incorporate data on patient populations that are historically underrepresented in clinical research. Indeed, information from a diverse patient population

Post-market safety data for underrepresented populations in clinical trials Read More »

Guidance on Informed Consent in Clinical Investigations

Blogs, Medical Writing, Regulatory /

Within the realm of clinical research, the process of obtaining informed consent stands as a crucial cornerstone of ethical practice, serving to protect the rights and well-being of human participants. The U.S. Food and Drug Administration (FDA) recognizes the changing landscape of clinical investigations and the necessity to align with the 2018 Common Rule and

Guidance on Informed Consent in Clinical Investigations Read More »

Drug Application Pathway

Understanding the FDA’s Abbreviated New Animal Drug Application Pathway

Insights, Regulatory /

The level of scrutiny surrounding animal medicinal products has strengthened more adverse events (AEs) associated with such products have emerged in animals. Indeed, AEs and adverse drug reactions (ADRs) is a cause of concern for veterinarians. Several cases of toxicity from commonly used drugs have been reported, in canines, for example. These include licosamides that

Understanding the FDA’s Abbreviated New Animal Drug Application Pathway Read More »

Public Health Emergencies

Mitigating medical device shortages in public health emergencies

Blogs, Medical Device, Regulatory /

The onset of the pandemic amplified an already growing concern in the European Union (EU)- the shortage of medicines, equipment, and devices that subsequently burdens the health system and puts patients at risk. Some of the reasons for these kinds of shortages are related to problems in manufacturing that can delay production, shortages of raw

Mitigating medical device shortages in public health emergencies Read More »

Digitalization in Regulatory Affairs

Digitalization in Regulatory Affairs

Blogs, Regulatory /

Technology is rapidly driving the growth of the Pharmaceutical and Life Sciences industries. With digital solutions being made more easily available, drug development & pharmacovigilance are transforming to become more efficient, compliant, and patient safety focused. However, regulatory affairs is still somewhat manual where processes and tasks are repetitive, siloed, and resource-heavy. Though Life Sciences

Digitalization in Regulatory Affairs Read More »